All In Biotech

Drug Trial Radar · NCT03449381

This Study Aims to Find the Best Dose of BI 907828 (Brigimadlin) in Patients With Different Types of Advanced Cancer (Solid Tumors)

A Phase Ia/Ib, Open Label, Multicenter, Dose-escalation Study of BI 907828 (Brigimadlin) in Patients With Advanced or Metastatic Solid Tumors

Last checked: Nov 19, 2026Latest source record: Mar 31, 2026 (this record)Source: ClinicalTrials.govMethods & limitations

Completed

Status

Completed

Enrollment

266

Actual

Start

Jun 20, 2018

Primary completion

Nov 13, 2025

Study completion Nov 13, 2025

Sponsor

Lead sponsor
Boehringer IngelheimBoehringer Ingelheim
Sponsor type
Industry
First posted
Feb 28, 2018

More drug trials from this sponsor

Design

Study type
Interventional
Phase
Phase 1
Allocation
Non randomized
Model
Sequential
Masking
None
Primary purpose
Treatment
FDA-regulated drug
Yes
Who can join
All sexes, from 18 years
Healthy volunteers
No

Summary

As written by the sponsor on the registry.

This study is open to adults with different types of advanced cancer (solid tumors). The purpose of this study is to find out the most suitable dose of BI 907828 (brigimadlin) the participants can tolerate. The most suitable dose is used in the second part to find out whether brigimadlin makes tumors shrink. In this study, brigimadlin is given to humans for the first time. Brigimadlin is a so-called MDM2 inhibitor that is being developed to treat cancer. Brigimadlin is taken as a tablet. Participants either take a dose of brigimadlin on one day every 3 weeks or on two days every 4 weeks. The participants are in the study for as long as they benefit from and can tolerate treatment. The doctors regularly check the participants' general health during the study.

Conditions

  • Neoplasms

Interventions

  • BI 907828Drug

    Film-coated tablet

Primary outcomes

What the sponsor says the trial is designed to measure.

  1. Phase Ia- Maximum tolerated dose (MTD) based on number of patients with dose limiting toxicities (DLTs) during first treatment cycleTime frame: Up to 28 days
  2. Phase Ib - Progression-free survivalTime frame: Up to 24 months
  3. Phase Ia - Number of patients with DLTs during first treatment cycle (21 days, Arm A; 28 days, Arm B)Time frame: Up to 28 days
  4. Phase Ib - Number of patients with DLTs during the first treatment cycleTime frame: Up to 28 days

Locations

27 sites in 11 countries. Site status is shown where the registry gives one.

  • Sarcoma Oncology Center

    Santa Monica, California

  • Yale University School of Medicine

    New Haven, Connecticut

  • Florida Cancer Specialists-Sarasota-61670

    Sarasota, Florida

  • Norton Cancer Institute, Downtown

    Louisville, Kentucky

  • START Midwest

    Grand Rapids, Michigan

  • Memorial Sloan-Kettering Cancer Center

    New York, New York

  • SCRI Oncology Partners

    Nashville, Tennessee

  • The University of Texas MD Anderson Cancer Center

    Houston, Texas

  • University of Wisconsin

    Madison, Wisconsin

  • Cliniques Universitaires Saint-Luc

    Brussels, Belgium

  • UZ Leuven

    Leuven, Belgium

  • The Ottawa Hospital

    Ottawa, Ontario, Canada

  • Rigshospitalet, København

    København Ø, Denmark

  • Helios Klinikum Berlin-Buch

    Berlin, Germany

  • Universitätsklinikum Köln (AöR)

    Cologne, Germany

  • Universitätsmedizin Göttingen, Georg-August-Universität

    Göttingen, Germany

  • Universitätsklinikum Tübingen

    Tübingen, Germany

  • Sourasky Medical Center

    Tel Aviv, Israel

  • National Cancer Center Hospital

    Tokyo, Chuo-ku, Japan

  • MED POLONIA SP Z O O, Clinical Trials Department,Poznan

    Poznan, Poland

  • Oncology Center-Maria Sklodowska-Curie Institute

    Warsaw, Poland

  • Severance Hospital

    Seoul, South Korea

  • Hospital Universitari Vall d'Hebron

    Barcelona, Spain

  • Hospital Clínic de Barcelona

    Barcelona, Spain

  • Fundación Jiménez Díaz

    Madrid, Spain

  • Hospital Clínico de Santiago

    Santiago de Compostela, Spain

  • Karolinska Comprehensive Cancer Center

    Stockholm, Sweden

Contact details for sites and study staff are not shown here. To ask about taking part, use the contact information on the registry record.

For information only. Nothing on this page is investment, legal, tax or medical advice, and nothing here is an offer to sell or a solicitation of an offer to buy any security. The data comes from public government sources, which can be incomplete, delayed or wrong. Check the original record before relying on it.